Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

After Jumping 100%, Is Axsome a Buy Before 2023?

TheMotleyFool

0 0

After Jumping 100%, Is Axsome a Buy Before 2023?: https://g.foolcdn.com/editorial/images/713135/biotech-pharma-researchers-talk-lab.jpg

Axsome Therapeutics (NASDAQ: AXSM) has done something most other stocks haven't been able to do this year: It's beaten the bear market. The shares are heading for a 111% gain as the S&P 500 heads for a 16% loss.

Axsome's performance isn't random -- there's a clear reason for it. This dynamic biotech company commercialized its first two products and is moving closer to possibly launching others in the next few years.

All of that sounds great. But you might be wondering if there's any share-performance potential left. After such gains, is Axsome still worth buying before 2023? Let's find out.

Source Fool.com

Like: 0

AXSM

Share